The study aimed to investigate the efficacy and safety of RC48 in HR-NMIBC as a novel treatment strategy. Researchers noticed that RC48, alone or with tislelizumab, demonstrates promising efficacy and manageable AE’s in patients with NMIBC. RC48 is a novel antibody-drug conjugate that targets the Her2 protein and has exhibited promising efficacy in […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Background Natural killer (NK) cell therapy is considered an attractive and safe strategy for anticancer therapy. Nevertheless, when autologous or allogenic NK cells are used alone, the clinical benefit has been disappointing. This is partially due …
Background Lenvatinib plus PD-1 inhibitors and interventional (LPI) therapy have demonstrated promising treatment effects in unresectable hepatocellular carcinoma (HCC). However, biomarkers for predicting the response to LPI therapy remain to be further explored. We aimed to …
Background Triple-negative breast cancer (TNBC) poses unique challenges due to its complex nature and the need for more effective treatments. Recent studies showed encouraging outcomes from combining paclitaxel (PTX) with programmed cell death protein-1 (PD-1) blockade …
Background Cervical cancer’s lymphatic spread primarily begins from the sentinel lymph nodes (SLNs), underlining their pivotal role in disease metastasis. However, these nodes’ immune gene expression profiles and immunoregulation mechanisms have yet to be explored. Methods Our study …
